(Circulation. 1995;91:2725-2732.)
© 1995 American Heart Association, Inc.
Articles |
More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction
Presented in part at the 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993.
From the University of Texas Medical School at Houston (R.W.S.); the Klinikum der Universität Heidelberg, Germany (C.B.); Cardiology of Tulsa (Okla), Inc (J.K.); the Medizinische Universitätsklinik Homburg/Saar, Germany (S.S.); the Stadtkrankenhaus Worms, Germany (P.L.); the Krankenhaus Neukoelln, Germany (F.F.); Baylor College of Medicine and VA Medical Center, Houston, Tex (G.H.); Munroe Regional Medical Center, Ocala, Fla (R.F.); the Klinikum der Universität Freiburg, Germany (S.H.); and Memorial Medical Center, Jacksonville, Fla (A.S.).
Background Early restoration and maintenance of normal (TIMI 3) blood flow during acute myocardial infarction is critical for optimal preservation of left ventricular function and survival. Recombinant plasminogen activator (r-PA, reteplase) is a nonglycosylated deletion mutant of wild-type tissue-type plasminogen activator (TPA) that has been shown to achieve more rapid and complete thrombolysis compared with other plasminogen activators in animal models.
Methods and Results The RAPID Trial was designed to test the hypothesis that bolus administration of one or more dosage regimens of r-PA was superior to standard-dose alteplase (TPA) in achieving infarct-related artery patency 90 minutes after initiation of treatment. Six hundred six patients with acute myocardial infarction were randomized to one of four treatment arms: (1) TPA 100 mg IV over 3 hours, (2) r-PA as a 15-MU single bolus, (3) r-PA as a 10-MU bolus followed by 5 MU 30 minutes later, or (4) r-PA as a 10-MU bolus followed by 10 MU 30 minutes later. Coronary arteriography was performed at 30, 60, and 90 minutes after initiation of treatment and at hospital discharge. The 10+10-MU r-PA group achieved better 90-minute and 5- to 14-day TIMI 3 flow (63% [CI, 55% to 71%] versus 49% [41% to 57%], P=.019, and 88% [82% to 94%] versus 71% [63% to 79%], P<.001, respectively) than the TPA group. The TIMI 3 flow in the 10+10-MU r-PA group at 60 minutes was equivalent to that in the TPA group at 90 minutes (51 versus 49%). Global ejection fraction and regional wall motion in the 10+10-MU r-PA group were superior to those of the TPA group at hospital discharge (53±1.3% versus 49±1.3%, P=.034; -2.19±0.12 versus -2.61±0.13 SD per chord, P=.02, respectively). The 15-MU and 10+5-MU r-PA patency and left ventricular function results were similar to those of the TPA and inferior to those of the 10+10-MU r-PA group. Bleeding complications were similar between the groups.
Conclusions r-PA given as a double bolus of 10+10 MU achieves more rapid, complete, and sustained thrombolysis of the infarct-related artery than standard-dose TPA, without an apparent increased risk of complications. This was associated with improved global and regional left ventricular function at hospital discharge.
Key Words: myocardial infarction • thrombolysis • plasminogen activators
This article has been cited by other articles:
 |
|
 |
|
  S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Sugg, E.A. Noser, H.M. Shaltoni, N.R. Gonzales, M.S. Campbell, R. Weir, E.D. Cacayorin, and J.C. Grotta Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am. J. Neuroradiol., April 1, 2006; 27(4): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mehta, J. H. Alexander, F. Van de Werf, P. W. Armstrong, K. S. Pieper, J. Garg, R. M. Califf, and C. B. Granger Relationship of Incorrect Dosing of Fibrinolytic Therapy and Clinical Outcomes JAMA, April 13, 2005; 293(14): 1746 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Dubois, A. Belmans, C. B. Granger, P. W. Armstrong, L. Wallentin, P. M. Fioretti, J. L. Lopez-Sendon, F. W. Verheugt, J. Meyer, F. Van de Werf, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson Confusion in reperfusion J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1186 - 1187. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman, R. C. Becker, J. E. Adams, S. Borzak, R. L. Jesse, L. K. Newby, P. O'Gara, J. C. Pezzullo, R. Kerber, B. Coleman, et al. Medication Errors in Acute Cardiac Care: An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke Circulation, November 12, 2002; 106(20): 2623 - 2629. [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]
|
|
|
|
|
|
J. A. de Lemos and E. Braunwald ST segment resolution as a tool for assessing the efficacy of reperfusion therapy J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1283 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1 Circulation, June 12, 2001; 103(23): 2862 - 2866. [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. Antman, J.A. de Lemos, and E. Braunwald Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A8 - A13. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, S. R. Mehta, J. Pogue, and S. Yusuf Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials: Intracranial Hemorrhage in Trials of Bolus Thrombolytic Therapy JAMA, January 24, 2001; 285(4): 444 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]
|
|
|
|
 |
|
 E.M Antman, C.M Gibson, J.A de Lemos, R.P Giugliano, C.H McCabe, P Coussement, I Menown, C.A Nienaber, T.C Rehders, M.J Frey, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14 Eur. Heart J., December 1, 2000; 21(23): 1944 - 1953. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Gibbons, T. D. Miller, and T. F. Christian Infarct Size Measured by Single Photon Emission Computed Tomographic Imaging With 99mTc-Sestamibi : A Measure of the Efficacy of Therapy in Acute Myocardial Infarction Circulation, January 4, 2000; 101(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]
|
|
|
|
 |
|
 E. J Topol CORONARY DISEASE: Acute myocardial infarction: thrombolysis Heart, January 1, 2000; 83(1): 122 - 122. [Full Text] [PDF]
|
|
|
|
|
|
M. Moser, T. Nordt, K. Peter, J. Ruef, B. Kohler, M. Schmittner, R. Smalling, W. Kubler, and C. Bode Platelet Function During and After Thrombolytic Therapy for Acute Myocardial Infarction With Reteplase, Alteplase, or Streptokinase Circulation, November 2, 1999; 100(18): 1858 - 1864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. French, T. A. Hyde, H. Patel, D. J. Amos, S. C. McLaughlin, B. J. Webber, and H. D. White Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks J. Am. Coll. Cardiol., July 1, 1999; 34(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Breuer, A. Schutz, B. Gansera, W. Eichinger, J. Weingartner, and B. Kemkes Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis Eur. J. Cardiothorac. Surg., March 1, 1999; 15(3): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. den Heijer, F. Vermeer, E. Ambrosioni, Z. Sadowski, J. L. Lopez-Sendon, R. von Essen, P. Beaufils, U. Thadani, J. Adgey, L. Pierard, et al. Evaluation of a Weight-Adjusted Single-Bolus Plasminogen Activator in Patients With Myocardial Infarction : A Double-Blind, Randomized Angiographic Trial of Lanoteplase Versus Alteplase Circulation, November 17, 1998; 98(20): 2117 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pislaru, C. Pislaru, M. Szilard, J. Arnout, and F. Van de Werf In vivo effects of contrast media on coronary thrombolysis J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf Thrombolysis for Acute Myocardial Infarction Circulation, April 28, 1998; 97(16): 1632 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L White Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update Asian Cardiovasc Thorac Ann, March 1, 1998; 6(1): 03 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Smalling and H. V. Anderson Pathophysiological Insight Into the Possible Optimal Therapies for Acute Myocardial Infarction and Unstable Angina Circulation, January 13, 1998; 97(1): 10 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Serebruany, P. A. Gurbel, A. R. Shustov, M. R. Dalesandro, C. I. Gumbs, L. B. Grabletz, R. D. Bahr, E. M. Ohman, and E. J. Topol Depressed Platelet Status in an Elderly Patient With Hemorrhagic Stroke After Thrombolysis for Acute Myocardial Infarction Stroke, January 1, 1998; 29(1): 235 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Global Use of Strategies to Open Occluded Coro A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction N. Engl. J. Med., October 16, 1997; 337(16): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bode, R. W. Smalling, G. Berg, C. Burnett, G. Lorch, J. M. Kalbfleisch, R. Chernoff, L. G. Christie, R. L. Feldman, A. A. Seals, et al. Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction Circulation, September 1, 1996; 94(5): 891 - 898. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Forrester New Standard for Success of Thrombolytic Therapy : An Earnest Proposal Circulation, October 15, 1995; 92(8): 2026 - 2028. [Full Text]
|
|
|
|
 |
|
 Better Thrombolysis with Reteplase Journal Watch Cardiology, August 1, 1995; 1995(801): 8 - 8. [Full Text]
|
|